Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.64
$0.491.19%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -7.03% | -24.58% | -34.18% | -72.21% | 39.59% |
| Total Depreciation and Amortization | 42.21% | 34.07% | 75.00% | 6.12% | 4.26% |
| Total Amortization of Deferred Charges | 9.90% | 9.78% | 13.58% | 3.85% | -17.02% |
| Total Other Non-Cash Items | -2.38% | 19.65% | 57.58% | 8.40% | -32.82% |
| Change in Net Operating Assets | -299.79% | -54.90% | 321.39% | -1,755.29% | 93.18% |
| Cash from Operations | -21.55% | -35.83% | -8.45% | -102.04% | 41.57% |
| Capital Expenditure | 100.00% | 52.35% | -131.47% | -167.72% | -32.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.61% | -26.41% | 457.67% | 113.36% | -52.71% |
| Cash from Investing | -62.32% | -26.09% | 467.49% | 112.95% | -52.68% |
| Total Debt Issued | -100.00% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.22% | 19,486.86% | 3,823.08% | -95.08% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -81.16% | 20,467.25% | -89.83% | 1,798.86% | 294.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -101.44% | 194.04% | 820.04% | 94.21% | -28.94% |